Stable Isotopes- Adults With Obesity

NCT ID: NCT07020741

Last Updated: 2025-10-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-12
• Study Completion Date: 2026-12-31

Brief Summary

In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.

Detailed Description

1. Enrollment, Informed Consent, and Screening Questionnaires (Virtual): Prior to study enrollment, participants will be asked to read a digital copy of an informed consent document provided using the e-Consent framework through the Research Electronic Data Capture (REDCap) system. Should participants have any questions about the study after reading the document, they will be encouraged to contact the research team prior to providing informed consent. Upon provision of informed consent, participants will receive an email with questionnaires designed to assess eligibility for the study through REDCap. Specifically, participants will be asked to complete a health and medical history questionnaire, physical activity readiness questionnaire (PARQ), International Physical Activity Questionnaire Long Form (IPAQ), and Godin-Shephard Leisure-Time Physical Activity Questionnaire (LTPAQ). Information from the medical history questionnaire, PARQ, and LTPAQ will be used to assess exclusion criteria and the IPAQ be used to assess baseline habitual activity level. Upon completion of these questionnaires, the research team will review responses and determine eligibility. Should Participants be eligible, researchers will work with the participant to schedule subsequent visits

2. Preliminary Testing (Visit 1): Participants will arrive for the preliminary testing session after an overnight fast.

Urine samples: 30mL of urine at time points -30 min, 0 min, 240 min, 300 min, and 360 min. Briefly, participants will be provided with a urine collection cup, alcohol wipes, and gloves and asked to fill the cup about 3/4 of they way.

Blood Collection: ~88 mL will be collected during the trial.

Breath Collection: At -30 minutes, 0 minutes, 120 minutes, 240 minutes, 300 minutes, 360 minutes, we will measure the air exhaled. To do this, participants breathe normally through a hose. Immediately after, they will exhale into a separate mouthpiece attached to a plastic bag.

Muscle Collection: A total of 2 muscle biopsies will be collected during the trial. The biopsy procedure involves removal of a small piece of muscle tissue using a sterile hollow needle (Bergström needle) and will be performed by Dr. Nicholas Burd under the auspices of Dr. Jared Willard, MD. Participants will rest on a bed and the area for the biopsy will be shaved, if required. Subsequently, the area will be sterilized using 4% chlorhexidine gluconate before 5 mL of local anesthetic (2% Xylocaine with 1:100,000 epinephrine) is injected subcutaneously with special care to avoid infiltrating the muscle. Once the anesthetic is active, a small incision will be made in the skin in order to create an opening through which to put the biopsy needle for tissue collection. Dr. Burd will quickly cut of a small piece of muscle. the subjects may feel a sensation of deep pressure in their leg. A sterile disposable drape will be placed under the participant's thigh and sterile gloves will be used for all biopsy procedures.

After the biopsy is completed, a trained research team member will apply pressure with sterile gauze until the bleeding stops (at least 15 minutes). Subsequently, the incision site will be closed using butterfly stitches (Steri-strips) following by application of a bandage. An elastic pressure wrap will be applied on top of the bandage in order to minimize the chance of bruising. Participants will then be instructed to leave the butterfly stitches and the pressure wrap on the wound for 96 and 24 hrs, respectively.

The participant will be provided with a "biopsy care kit" (described in section 10.1/Biopsy care kit) in order to properly care for the incision after leaving the laboratory. A member of the research team will contact the participants in the day following the trial to check on the healing process.

After blood, breath, and muscle samples of time 0, participants will drink the first of a series of drinks containing [13C]phenylalanine and [2H5]phenylalanine at a ratio of 1:10 with a 1:10 ratio of total tracer to tracee (naturally occurring phenylalanine) The first drink will be primed with NaH13CO2 (0.176 mg/kg) in addition to [13C]phenylalanine and [2H5]phenylalanine mixture. Drinks will be consumed every 30 minutes for the duration of the procedure.

These drink will also contain 1.2x estimated RMR calories (divided into 12 drinks)

VCo2: Carbon dioxide production (VCO2) will be determined from expired air sampled by open circuit spirometry using an on-line, computer-based acquisition system. Participants will breathe through a one-way, high velocity non-rebreathing valve. The volume of expired air is measured by a gas flow meter. The carbon dioxide concentrations of expired air are assessed by a carbon dioxide analyser. Analog data from the gas analyser and flow meter is digitized and sent to an IBM compatible PC for calculation of VCO2 converted to Standard Temperature and Pressure Dry. Immediately after VCO2 analysis is performed (5 min), subjects are asked to exhale into a separate mouthpiece attached to a plastic bag. This particular breath sample is stored in a sterile vacutainer for future analysis of stable isotope tracer enrichment in the breath. The measurement of carbon dioxide production (VCO2) and the measurement of tracer enrichment in the breath allow us to assess how much of the protein is used for energy, rather than for building skeletal muscle proteins. Subjects are not expected to experience any discomfort from this procedure, nor will it influence their physical well-being.

(Visit 4) Stable Isotope OGTT: within 7 days after the first trail participants will be asked to return to the lab for a second procedure.

Blood Collection: Blood collection procedures will be exactly as described above. There will be a total of 9 blood collections (time -10, 10, 20, 30, 60. 90, 120, 150, 180) minutes Breath Collection: Breath collection procedures will be exactly as described above. There will be a total of 9 breath collections (-10, 10, 20, 30, 60, 90, 120, 150, 180) minutes After the blood and breath collection for time -10 minutes, participants will be asked to consume a 75 g Glucose Drink dissolved in 250 ml of water enriched with [6,6_2H2]glucose and [13C6]glucose. As stated above, blood and breath samples will be taken periodically over the next 3 hours.

Conditions

Obese Patients (BMI ≥ 30 kg/m²); Glucose Metabolism; Protein Metabolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IAAO

Participants will ingest a series of 6 hourly beverages containing 50% of the daily intake of 1.1g/kg/day

Group Type: EXPERIMENTAL

Indispensable Amino Acid Oxidation

Intervention Type: PROCEDURE

Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.

SIOGTT

Participants will consume one 75g glucose drink dissolved in 250 ml of water.

Group Type: EXPERIMENTAL

Stable Isotope Oral Glucose Tolerance Test

Intervention Type: PROCEDURE

Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.

Interventions

Indispensable Amino Acid Oxidation

Participants will ingest six hourly meals designed to provide 50% of the daily intake of 1.1 g·kgLBM. Additional energy (1.5x daily resting metabolic rate), carbohydrate (55%), and fat (35%) will be provided in beverages and protein-free cookies (for palatability). The first drink will contain priming doses of NaH13CO2 (0.176 mg·kg-1), \[13C\]phenylalanine (1.86 mg·kg-1), \[2H5\]phenylalanine (0.34 mg·kg-1) with all subsequent drinks containing 1.2 mg·kg-1 \[13C\]phenylalanine and 0.51 mg·kg-1 \[2H5\]phenylalanine.

Intervention Type: PROCEDURE

Stable Isotope Oral Glucose Tolerance Test

Participants will consume a 75g glucose drink dissolved in 250 ml of water enriched with \[6,6\_2H2\]glucose and \[13C6\]glucose.

Intervention Type: PROCEDURE

Other Intervention Names

IAAO; Si OGTT

Eligibility Criteria

Inclusion Criteria

• ages 19-59
• Obese >/= 30 kg/m^2 and >/= 102 cm for males and >/= 88 cm for females
• Godin Leisure-time or exercise questionnaire <14 units

Exclusion Criteria

1. Pregnant or become pregnant

2. Any known food allergies

3. Smoker

4. Are physically active

5. Have any known metabolic diseases

6. Have been weight unstable within the last 6 months (lost or gained >10% of body mass)

7. Non eumenorrheic or on a hormonal birth control

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 59 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Illinois at Urbana-Champaign

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Freer Hall - University of Illinois

Urbana, Illinois, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Nicholas Burd (Associate Professor), PhD

Role: CONTACT

naburd@illinois.edu

2172440970

Gena L Irwin (Research Assistant), M.S

Role: CONTACT

genai2@illinois.edu

3608883281

Facility Contacts

Nicholas Burd (Associate Professor), PhD

Role: primary

naburd@illinois.edu

2172440970

Gena L Irwin Research Assistant, M.S

Role: backup

genai2@illinois.edu

3608883281

Other Identifiers

RB25064

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB25-0166

Identifier Type: -

Identifier Source: org_study_id